Beecham Group plc and SmithKline Beecham Pharmaceuticals (Pty) Ltd v Triomed (Pty) Ltd

Beecham Group plc and its subsidiary marketed the antibiotic Augmentin. After expiry of its patent on the drug composition, Beecham relied on a registered trade mark for the shape of its Augmentin tablet, described as a substantially oval, bi‑convex tablet, registered in 1995 for antibiotics. Triomed imported and sold a generic equivalent with the same composition under the name Augmaxcil. The Augmaxcil tablets were white and of the same shape and size as Augmentin tablets but bore no embossing. Triomed applied to the Transvaal Provincial Division for rectification of the Trade Marks Register to expunge Beecham’s shape mark. Beecham counter‑applied for trade mark infringement relief based on both the shape mark and the word mark ‘Augmentin’. The High Court ordered expungement of the shape mark and dismissed Beecham’s counter‑application (except that the word‑mark issue was not appealed). Beecham appealed to the Supreme Court of Appeal.

The appeal was dismissed. The order of the Transvaal Provincial Division expunging Beecham’s registered shape trade mark from the Trade Marks Register was upheld.

This case is a leading South African authority on the registrability and validity of shape trade marks, particularly in the pharmaceutical context. It clarifies the limits of trade mark protection for functional product shapes and reinforces the principle that trade mark law should not be used to extend monopoly protection after patent expiry. The judgment aligns South African trade mark law with European jurisprudence while emphasising local policy considerations, and it underscores the distinction between product recognition and trade mark distinctiveness.